By Akanksha
Drug sponsors have faced significant delays before starting the first-in-human trials. These bottlenecks originate from skepticism regarding regulatory requirements, frequently leading sponsors to conduct pointless studies. Along with extended wait periods for Institutional Review Board (IRB) approvals and protocol amendments, the U.S. drug development pathway has faced significant complications.
To solve this, the FDA is introducing a rolling review model — regulatory procedure in which data is submitted and analyzed continuously as it becomes available, instead of waiting for a complete result — encouraging the parallel coordination of clinical startup activities (for example simultaneous IRB reviews and trial site activation), among the FDAs ongoing IND review.
Operation Trialblazer was launched to manage competitive pressures from foreign markets that initiate global trials significantly faster than the U.S.
Although the FDA’s standard 30-day IND review matches the global competitors, administrative problems within the system, for instance Institutional Review Board (IRB) reviews and site contract negotiations, can delay the clinical trials by more than a year.
| Country | Regulatory Review | Trial Initiation Timeframe |
|---|---|---|
| Australia | 21 to 28 days | Under 70 days |
| China | Expendited (Discovery to IND is 50 to 70% faster) | Within 12 weeks of IND submission |
| Unites States | 30 Days | Upto 13 months (administrative delays) |
To eliminate these regulatory and administrative bottlenecks, the FDA is adopting partnerships between drug sponsors and Qualified Research Institutions (QRIs) — which involves academic medical centers, health networks, regulatory advisors, and contract research organizations — who will act as scientific experts, providing their guidance on pharmacology, toxicology, and chemistry, manufacturing, and controls (CMC) — for FIH IND submissions.
“The pilot not only pairs industry innovators with top research institutions to accelerate high-quality data being submitted to the FDA, it also tests if the partnership can accelerate what happens after the FDA allows a clinical trial to proceed. Under the Trump Administration, boosting domestic innovation and ensuring American patients have first access to groundbreaking treatments is a top priority,” said Kyle Diamantas, Acting FDA Commissioner in the FDA news release.
June 24, 2026 : FDA sought feedback on launching the expedited pre-IND rolling review framework.
July 21, 2026 : Comment deadline was extended to allow life science companies, academic centers, and trade groups (like BIO) submit technical feedback on QRI qualifications and conflict-of-interest criteria.
September 15, 2026 : FDA launched the program and opened the application window
October 30, 2026 : Deadline for sponsors to submit applications
December 18, 2026 : FDA selects the participant cohort and notifies all applicants.
(Note: Timeline is subject to the number of submissions received)
Improve submission quality and phase-appropriate data for human-first INDs.
Earlier Identification and resolution of scientific and regulatory problems.
Fewer Phase I clinical holds or information requests.
Efficient progression through nonclinical development of FIH initiation.
Greater coordination of startup activities, including simultaneous IRB reviews and clinical site readiness.
The FDA will assess applications as a single, combined proposal consisting of both the sponsor and their partnered QRI, and aims for the group that mirrors a wide diversity of therapeutic areas, product methods, sponsor sizes, and QRI types. No single factor is conclusive.
The FDA will prioritize applicants who submit for a single IND and meet the following criteria.
The proposed drug candidate is a novel and falls under the control of CDER office of New Drugs (OND), CBER Office of Therapeutic Products (OTP), or Oncology Center of Excellence (OCE).
The Sponsor intends to eventually commercialize the product.
The Program aims Phase I First-in-Human (FIH) trials to be conducted in the U.S.
The investigational product has no previous clinical experience.
The Sponsor has sufficient non-clinical data at the time of application to allow the FDA to assess the proposed timeline.
(Note: although novel platforms are allowed, pilot support is restricted to the specific technology incorporated into the submitted IND, instead of the broader platform.)
The personnel have to be located domestically, organized and incorporated in the U.S. as a principal place of business.
Commits to provide IND development or advisory support over non-clinical, CMC, and clinical disciplines for the sponsor’s application.
Commits to speed up Phase I FIH trial initiation in the U.S. utilizing owned infrastructure or officially recorded partnership arrangements.
The FDA’s Expedited IND Pilot Program, launched under the Operation TrialBlazer, combines drug sponsors with Qualified Research institutions (QRIs) to speed up the first in human (FIH) clinical trials. Consequent regulatory reviews and administrative difficulties (like, IRB approvals) currently delay U.S. trial initiation by approximately 13 months, causing the U.S. to lag behind faster markets like, Australia and China. A rolling regulatory review model is implemented using the influence of third party QRI expertise to resolve pharmacology, clinical, and CMC problems in parallel to the trial site activation. The Pilot program aims to reduce approximately 6 to 12 months of the development timeline. Solving issues simultaneously can help bypass clinical holds and maintain U.S. leadership in pharmaceutical innovation without compromising safety of the patients.
References:
U.S. Food and Drug Administration. “FDA Expedited Investigational New Drug (IND) Pilot Program.” U.S. Food and Drug Administration. https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development/fda-expedited-investigational-new-drug-ind-pilot-program.
U.S. Food and Drug Administration. “FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development.” U.S. Food and Drug Administration. https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development.
U.S. Food and Drug Administration. “FDA Launches Expedited IND Pilot, Begins Accepting Applications.” U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-launches-expedited-ind-pilot-begins-accepting-applications.
1. U.S. Department of Health and Human Services. Operation TrialBlazer: HHS Roadmap to Maintaining U.S. Leadership in Early Clinical Research and Development. 2026. https://www.hhs.gov/sites/default/files/operation-trialblazer.pdf.
(Rh/APC/MSM)